Amgen Defends Neulasta Patent in Biosimilar Suit against Coherus
Amgen is suing Coherus Biosciences over its processes for manufacturing a biosimilar of Neulasta, saying it infringes patented methods for purifying proteins.
Source: Generic Line
Amgen is suing Coherus Biosciences over its processes for manufacturing a biosimilar of Neulasta, saying it infringes patented methods for purifying proteins.
Source: Generic Line